

1624 \$

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 01-1693-M)
(previously 13615.41USU1)

TECH CENTER 1600/2900

RECEIVED

FEB 14 2003

In re Application of:)

Beck et al.)

Serial No.: 09/895,843)

Filed: June 29, 2001)

For: Compounds to Treat Alzheimer's Disease)

Before the Examiner:

Sudhaker B. Patel

Art Unit: 1624

Confirmation No.: 5924

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:

- a. Petition for Three Month Extension of Time;
- b. Response to the Restriction Requirement Mailed October 1, 2002; and
- c. Postcard.

2. With respect to additional fees:

A. Attached is a check in the amount of \$930.00.

3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 31ST day of January 2003.

Date: January 31, 2003

By:

Steven J. Sarussi
Reg. No. 32,784

#14


BEST AVAILABLE COPY

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

on January 31, 2003 (Date of Deposit). *4/29*

1/31/03 *JH* Date Name



TECH CENTER 1600/2900
FEB 14 2003

RECEIVED

FEB 14 2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 01-1693-M)

In re Application of:)
Beck et al.)
Serial No.: 09/895,843) Before the Examiner:
Filed: June 29, 2001) Sudhaker B. Patel
For: Compounds to Treat) Art Unit: 1624
Alzheimer's Disease)
)

RESPONSE TO THE RESTRICTION REQUIREMENT
MAILED OCTOBER 1, 2002

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Responsive to the Restriction Requirement
mailed October 1, 2002, the Applicants elect the claims of Group
IX, i.e., Claims 15-35, 64-98 (in part), 104-109 (in part), 116-
121, 125-127, 130-131, 139-145, 147, 151-153, 156-157, 167, 173,
and 175 for prosecution. Further, Applicant elect the species
of Preparation 23, page 131, lines 10-11. That compound is

named N¹-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-N³,N³-dipropylisophthalamide.

Claims 15, 16-21, 29-35, 64-98, 104-109, 116-121, 125-127, 130-131, 139-145, 147, 151-153, 156-157, 167, 173, and 175 encompass the elected species.


REMARKS

Allowance of the claims and passage of the case to issue are respectfully solicited. The Applicants urge the Examiner to contact the Applicants' undersigned representative as (312) 913-0001 should he believe that this would expedite prosecution of this application.

Respectfully submitted,

Dated: January 31, 2003

By:


Steven J. Sarussi
Reg. No. 32,784

McDonnell Boehnen
Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001